

Molecular Analysis of *Acinetobacter baumannii* Strains Isolated in Lebanon Using Four Different Typing Methods

Rayane Rafei, Fouad Dabboussi, Monzer Hamze, Matthieu Eveillard, Carole Lemarié, Marie-Pierre Gaultier, Hassan Mallat, Rima Moghnieh, Rola Husni-Samaha, Marie-Laure Joly-Guillou, et al.

► **To cite this version:**

Rayane Rafei, Fouad Dabboussi, Monzer Hamze, Matthieu Eveillard, Carole Lemarié, et al.. Molecular Analysis of *Acinetobacter baumannii* Strains Isolated in Lebanon Using Four Different Typing Methods. PLoS ONE, Public Library of Science, 2014, 9 (12), pp.e115969. 10.1371/journal.pone.0115969 . hal-03333787

HAL Id: hal-03333787

<https://hal.univ-angers.fr/hal-03333787>

Submitted on 3 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



RESEARCH ARTICLE

Molecular Analysis of *Acinetobacter baumannii* Strains Isolated in Lebanon Using Four Different Typing Methods

Rayane Rafei^{1,2}, Fouad Dabboussi², Monzer Hamze², Matthieu Eveillard^{1,3}, Carole Lemarié³, Marie-Pierre Gaultier³, Hassan Mallat², Rima Moghnieh⁴, Rola Husni-Samaha⁵, Marie-Laure Joly-Guillou^{1,3}, Marie Kempf^{1,3*}

1. L'UNAM Université, Université d'Angers, Groupe d'Etude des Interactions Hôte-Pathogène, UPRES EA3142, Institut de Biologie en Santé – IRIS, CHU, Angers cedex, France, 2. Laboratoire de Santé et environnement, Centre AZM pour la recherche en Biotechnologie et ses applications, Université Libanaise, Tripoli, Liban, 3. Laboratoire de Bactériologie, Institut de Biologie en Santé - PBH, CHU, Angers cedex, France, 4. Ain wa zein Hospital, Shouf, Lebanon, 5. Division of Infectious Diseases, Department of Internal Medicine, Lebanese American University Medical Center Rizk Hospital, Beirut, Lebanon

*makempf@chu-angers.fr



CrossMark
click for updates

OPEN ACCESS

Citation: Rafei R, Dabboussi F, Hamze M, Eveillard M, Lemarié C, et al. (2014) Molecular Analysis of *Acinetobacter baumannii* Strains Isolated in Lebanon Using Four Different Typing Methods. PLoS ONE 9(12): e115969. doi:10.1371/journal.pone.0115969

Editor: Ramin M. Hakami, George Mason University, United States of America

Received: June 11, 2014

Accepted: December 3, 2014

Published: December 26, 2014

Copyright: © 2014 Rafei et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

This study analyzed 42 *Acinetobacter baumannii* strains collected between 2009–2012 from different hospitals in Beyrouth and North Lebanon to better understand the epidemiology and carbapenem resistance mechanisms in our collection and to compare the robustness of pulsed field gel electrophoresis (PFGE), multilocus sequence typing (MLST), repetitive sequence-based PCR (rep-PCR) and *bla*_{OXA-51} sequence-based typing (SBT). Among 31 carbapenem resistant strains, we have detected three carbapenem resistance genes: 28 carried the *bla*_{OXA-23} gene, 1 the *bla*_{OXA-24} gene and 2 strains the *bla*_{OXA-58} gene. This is the first detection of *bla*_{OXA-23} and *bla*_{OXA-24} in Lebanon. PFGE identified 11 types and was the most discriminating technique followed by rep-PCR (9 types), *bla*_{OXA-51} SBT (8 types) and MLST (7 types). The PFGE type A/ST2 was the dominant genotype in our collection present in Beyrouth and North Lebanon. The clustering agreement between all techniques was measured by adjust Wallace coefficient. An overall agreement has been demonstrated. High values of adjust Wallace coefficient were found with followed combinations: PFGE to predict MLST types = 100%, PFGE to predict *bla*_{OXA-51} SBT = 100%, *bla*_{OXA-51} SBT to predict MLST = 100%, MLST to predict *bla*_{OXA-51} SBT = 84.7%, rep-PCR to predict MLST = 81.5%, PFGE to predict rep-PCR = 69% and rep-PCR to predict *bla*_{OXA-51} SBT = 67.2%. PFGE and MLST are gold standard methods for outbreaks investigation and population structure studies respectively. Otherwise, these two techniques are technically, time and cost demanding. We recommend the use of *bla*_{OXA-51} SBT as first typing method to

screen isolates and assign them to their corresponding clonal lineages. Repetitive sequence-based PCR is a rapid tool to access outbreaks but careful interpretation of results must be always performed.

Introduction

Acinetobacter baumannii is an opportunistic gram negative pathogen involved in a wide number of nosocomial infections like ventilator-associated pneumonia, bloodstream, urinary tract, wound and meningitis infections frequently associated with a high rate of mortality and morbidity [1]. Outbreaks have been intensively documented worldwide and are usually caused by multidrug resistant strains and more and more carbapenem resistant strains [2,3]. These outbreaks strains mainly belonged to three international clones I, II and III (previously called as European clones [4,5]), but also to different clonal lineages. Karah *et al.* [2] analyzed the MLST-based global population structure of *A. baumannii* on 496 isolates. They showed the presence of 26 clones and among them, 18 were international clones and 8 European or Asian restricted clones. The International clone II was the major clone reported in 34 countries in Europe, Asia, Africa Australia, USA, and South America.

To track and monitor these outbreaks, denote strain relatedness and assign an outbreak strain to its corresponding clonal lineage, many typing methods with different intrinsic degrees of resolution are proposed [3] such as pulsed field gel electrophoresis (PFGE) [6], repetitive-sequence-based PCR (rep-PCR) [7], amplified fragment length polymorphism (AFLP) [8], multilocus sequence typing (MLST) [9,10], 3-locus sequence typing (3-LST) [11], *bla*_{OXA-51} sequence-based typing (SBT) [12] or Multiple-Locus Variable number of tandem repeat Analysis (MLVA) [13]. Selection of an appropriate genotyping technique is not always easy and depends to the studied objectives. Many authors emphasized the great need to validate the application of each method as well as to harmonize different typing methods by reference networks [3,14]. Among these methods, PFGE is still considered the current gold standard for *A. baumannii* outbreak investigation at local scale [3]. MLST has a discriminatory power lesser than PFGE and is regarded as the gold standard for large epidemiological and population structure studies. For *A. baumannii*, two MLST schemes have been proposed: Bartual's MLST [9] and Pasteur's MLST [10]. DiversiLab is a semi-automated form of rep-PCR with a comparable discriminatory power to PFGE [15]. The identification of eight international clones is one of the remarkable advantages of this system [7]. *bla*_{OXA-51} SBT has been proposed as a single-locus based typing [12] with a similar discriminatory power to rep-PCR [16] and Bartual and Pasteur's MLST [12,17].

In Lebanon, there have been limited reports studying only local outbreaks in Beyrouth between 2004 and 2007 where *bla*_{OXA-58} was the only carbapenem resistance gene identified [18–20]. Recently, we have detected four *bla*_{NDM-1}

producing *A. baumannii* isolated in Tripoli, Northern Lebanon from Syrian civilians wounded during Syrian war [21].

The present study has a double aim: firstly to compare the performance and effectiveness of four epidemiological typing methods (PFGE, rep-PCR, MLST and *bla*_{OXA-51-like} SBT), and secondary to get primary results on circulating clones and carbapenem resistance mechanisms in Lebanon by analysis of 42 non duplicate strains conserved on Azm center for research on biotechnology and its application (Lebanese university) and collected between 2006–2012 from different hospitals in Beyrouth and North Lebanon.

Results

Identification

Forty-two strains were confirmed as *A. baumannii* by molecular techniques. These strains were isolated in different hospitals in Beyrouth (24 strains) and North Lebanon (18 strains) from various clinical specimens between 2009 and 2012 except one strain isolated in 2006 (Table 1). Beyrouth strains were isolated during epidemiological contexts.

Carbapenem resistance mechanisms

Thirty-one strains showed carbapenem resistance phenotypes (Fig. 1). Among these strains, 28 harbored a *bla*_{OXA-23} gene, 2 a *bla*_{OXA-58} gene, and one a *bla*_{OXA-24} gene. No acquired *bla*_{ndm-1} or *bla*_{OXA-143} has been detected. *ISAbal* was present in 37 strains. All carbapenem resistant strains except one (strain 53, *bla*_{OXA-24} positive) had this sequence in their genomes whereas 7 carbapenem susceptible strains only had this sequence. The research of *ISAbal* presence before both *bla*_{OXA-51} and *bla*_{OXA-23} genes revealed its insertion upstream *bla*_{OXA-23} in *bla*_{OXA-23} producing strains but not upstream *bla*_{OXA-51} gene in both carbapenem resistant or susceptible strains. This insertion explains the high level of resistance to carbapenems (imipenem MIC>32, meropenem MIC>32, doripenem 12<MIC>32) for all *bla*_{OXA-23} producing *A. baumannii* strains. The *bla*_{OXA-24}-producing strain (strain 53) had MIC: 8 mg/l, 16 mg/l, 16 mg/l for imipenem, meropenem and doripenem respectively, whereas the two *bla*_{OXA-58} - producing strains (strain 58 and 23) showed low level of carbapenem resistance: (4; 8 mg/l), (2; 4 mg/l), (2; 3 mg/l) for imipenem, meropenem and doripenem respectively.

Epidemiological typing

PFGE

Using ≥80% similarity cut-off as a threshold, PFGE classified our strains in 11 types: 4 clusters (A' to D') and 7 unique profiles (Fig. 1). Cluster A' comprised 28 strains, 27 were *bla*_{OXA-23} producing strains and one an imipenem susceptible strain. This cluster contained strains from Beyrouth and North Lebanon. Cluster B' contained two *bla*_{OXA-58} producing strains that belonged to the same hospital.

Table 1. Origin and repartition of strains used in this study.

Strain ID	Hospital	City	Department	Gender	Age	Period study	Sample origin
8	Nini	Tripoli	ICU	M	70	2009	tracheal aspirate
9	RHH	Beyrouth	ICU	M	79	2011	blood
13	RHH	Beyrouth	NA	NA	NA	2011	NA
15	RHH	Beyrouth	ICU	M	68	2011	blood
17	Nini	Tripoli	Cardiology	M	48	2009	urine
19	RHH	Beyrouth	NA	NA	NA	2011	NA
20	RHH	Beyrouth	ICU	F	69	2011	blood
21	RHH	Beyrouth	NA	NA	NA	2011	NA
22	RHH	Beyrouth	NA	NA	NA	2011	NA
23	AWH	Beyrouth	NA	M	89	2011	rectum
24	RHH	Beyrouth	ICU	M	54	2011	blood
25	RHH	Beyrouth	NA	NA	NA	2011	NA
28	Nini	Tripoli	Outpatient	F	51	2011	urine
29	Nini	Tripoli	NA	F	22	2011	urine
30	RHH	Beyrouth	NA	NA	NA	2011	NA
31	Nini	Tripoli	ICU	M	72	2011	tracheal aspirate
34	RHH	Beyrouth	NA	NA	NA	2011	NA
35	Nini	Tripoli	Outpatient	M	37	2011	bedsore
36	Nini	Tripoli	ICU	M	74	2012	tracheal aspirate
37	AWH	Beyrouth	NA	M	89	2011	throat
38	Nini	Tripoli	Cardiology	M	57	2006	tracheal aspirate
40	Nini	Tripoli	ICU	M	20	2012	blood
41	RHH	Beyrouth	NA	NA	NA	2011	NA
45	RHH	Beyrouth	NA	NA	NA	2011	NA
46	Monla	Tripoli	NA	M	37	2012	chest drain
47	AWH	Beyrouth	NA	F	65	2011	sputum
48	RHH	Beyrouth	NA	M	74	2011	blood
49	RHH	Beyrouth	NA	NA	NA	2011	NA
50	RHH	Beyrouth	NA	NA	NA	2011	NA
51	RHH	Beyrouth	NA	NA	NA	2011	NA
52	RHH	Beyrouth	NA	NA	NA	2011	NA
53	Nini	Tripoli	Maternity	F	25	2010	urine
56	Nini	Tripoli	ICU	F	79	2011	bronchial aspirate
58	AWH	Beyrouth	NA	F	39	2011	sputum
59	RHH	Beyrouth	NA	F	70	2011	blood
60	RHH	Beyrouth	NA	NA	NA	2011	NA
62	Nini	Tripoli	Outpatient	F	74	2012	urine
63	Rahal	Akkar	Internal medicine	M	46	2012	wound
65	TGH	Tripoli	Internal medicine	M	27	2012	wound
66	TGH	Tripoli	ICU	M	29	2012	sputum
67	TGH	Tripoli	Internal medicine	F	38	2012	abdomen
68	TGH	Tripoli	Internal medicine	M	29	2012	sputum

AWH: Ain Wazein Hospital; RHH: Rafic Hariri Hospital; TGH: Tripoli Governmental Hospital; ICU: Intensive care unit; NA: not available.

doi:10.1371/journal.pone.0115969.t001

Cluster C' and D' contained two and three imipenem susceptible strains respectively.

MLST

MLST typing was performed on all strains. Seven ST(s) were identified (Fig. 1), two of which were novel and assigned as 284 and 285 by MLST Pasteur. The ST2 was the most predominant, present in 34 strains, followed by ST25, present in 3 strains; other ST(s) were present sporadically in our collection. The eBUSRT analysis of our ST(s) with all identified ST(s) in MLST database (28.03.2014) showed that ST 1, 2, 3, 25, 284 belonged to CC 1, 2, 3, 25 and 33 respectively, whereas ST285 was a singleton, and ST108 shared similarity with ST112 (we did not assign a name for this complex because no more of 2 ST(s) have been yet identified). Interestingly, our novel ST284 was a SLV of ST33 (the founder of CC33).

rep-PCR

Using $\geq 95\%$ similarity cut-off as a threshold, rep-PCR identified 9 types (Fig. 1): 3 clusters (cluster A to C) and 6 unique profiles (ungrouped strains). Cluster A was the major cluster which contained 31 strains, whereas cluster B and C contained 2 and 3 strains respectively. Cluster A grouped only strains belonging to clone EU II except one strain (strain 62) belonging to EU clone III. This cluster comprised strains from different hospitals in Beyrouth (22 strains) and from North Lebanon (9 strains). Cluster B comprised two imipenem susceptible strains from Tripoli and Beyrouth, while cluster C contained all strains belonging to ST25 and coming from one hospital in Tripoli. Two unclustered strains belonged to ST2 while the remaining strains belonged to different ST(s).

*bla*_{OXA-51-like} sequence-based typing

*bla*_{OXA-51} SBT has been performed with randomly selected strains from rep-PCR type A, and for all remaining strains. Notably, *bla*_{OXA-51} SBT correctly identified our strains. All strains belonging to ST2 (CC2) carried the *bla*_{OXA-66} gene, except one strain (strain 17) which was a colistin resistant one and which carried a single amino acid variant of OXA-66 described for the first time in this study (OXA-336, KF048907). The *bla*_{OXA-336} had a non-synonymous mutation from *bla*_{OXA-66} at nucleotide 518 (thymine became adenine) which led to the substitution of isoleucine by asparagine at amino acid 173. For the other strains, each ST had a unique OXA-51 type: ST1 carried OXA-69, ST3 OXA -71, ST25 OXA-64, ST108 OXA-132, ST284 OXA-120, and ST285 a new OXA (OXA-337, KF048908).

Comparison of the four typing methods

The visual analysis of the collection (Fig. 1) showed an overall agreement between the different techniques, although some discrepancies have been noticed. The adjusted Wallace coefficient analysis (Table 2) revealed that all ST(s) obtained by MLST were predicted at 100% level by PFGE and *bla*_{OXA-51} SBT and at 81.5% by rep-PCR. Conversely, MLST was unable to predict PFGE and rep-PCR types, but able to well predict *bla*_{OXA-51} sequences (84.7%). As expected, PFGE types were




Fig. 1. PFGE, MLST, DiversiLab and *bla*_{OXA-51-like} comparison results for 42 *A. baumannii* strains. Dendrogram was generated by cluster analysis of PFGE fingerprinting patterns. Arrow shows the adopted cut-off (80%) for definition of PFGE type. ID: Sample number, rep-PCR for rep-PCR type, IMP: imipenem susceptibility (S for susceptible and R for resistant), OXA: oxacillinase responsible for carbapenem resistance phenotype.

doi:10.1371/journal.pone.0115969.g001

Table 2. Concordance between the studied typing techniques using adjusted Wallace coefficient (95% confidence interval).

	PFGE (cut-off 80%)	rep-PCR (cut-off 95%)	MLST	bla _{OXA-51} SBT
PFGE		0.690 (0.313–1.000)	1.000 (1.000–1.000)	1.000 (1.000–1.000)
rep-PCR	0.462 (0.086–0.838)		0.815 (0.473–1.000)	0.672 (0.259–1.000)
MLST	0.422 (0.058–0.786)	0.513 (0.107–0.919)		0.847 (0.564–1.000)
bla _{OXA-51} SBT	0.498 (0.142–0.854)	0.499 (0.085–0.914)	1.000 (1.000–1.000)	

doi:10.1371/journal.pone.0115969.t002

not predicted by any other technique. In contrast, PFGE predicted at 100% level all ST(s) and *bla*_{OXA-51} sequences and at 69% rep-PCR types. Rep-PCR types were well predicted (69.0%) by PFGE, but not predicted neither by MLST nor by *bla*_{OXA-51} SBT. In contrast, rep-PCR predicted the ST(s) at 81.5% and *bla*_{OXA-51} at 67.2% but was unable to predict PFGE types. Finally for *bla*_{OXA-51} SBT, we have assumed that isolates belonging to ST2 and for which we didn't perform *bla*_{OXA-51} sequencing carried *bla*_{OXA-66} [17]. *bla*_{OXA-51} sequences were all predicted by PFGE, and at 84.7% and 67.2% by MLST and rep-PCR respectively. Conversely *bla*_{OXA-51} SBT was able to predict all ST(s), but not PFGE and rep-PCR types.

Discussion

This is the first study in Lebanon providing data about clonality and carbapenem resistance mechanisms of a set of isolates recovered from different hospitals in Beyrouth and North Lebanon. However, this study does not illustrate the overall *A. baumannii* molecular epidemiology in this country because it does not contain prospectively collected isolates from different hospitals in different Lebanese provinces.

Currently, worldwide carbapenem resistant strains are mostly associated with international clone 2 [2], with *bla*_{OXA-23} as the main carbapenem resistance mechanism [22–24]. Our results stick well to the global situation where the majority of carbapenem resistant strains belonged to ST2, but only two imipenem resistant strains in our collection belonged to ST1 and ST285 (Fig. 1). In several countries, *bla*_{OXA-58} [25] or *bla*_{OXA-24} [26] have been progressively replaced by *bla*_{OXA-23}. In Beyrouth-Lebanon, the studied outbreaks between 2004–2007 [18–20] were caused by the three international clones (1 to 3) producing OXA-58 as a main carbapenem resistance mechanism. In the present study, we detected *bla*_{OXA-58} in two strains from a hospital in Beyrouth, but *bla*_{OXA-23} seemed to be an emerging carbapenemase in Beyrouth and North Lebanon as else. Emergence of *bla*_{OXA-23} in Lebanon is linked to the clonal spread of the PFGE type A'/ST2. It is noteworthy that we reported in this study the first detection of *bla*_{OXA-23} and *bla*_{OXA-24} in Lebanon. Interestingly, the PFGE type A'/ST2 (harboring *bla*_{OXA-66}) dominated heavily in Beyrouth and North Lebanon suggesting an extensively inter-hospital dissemination and thus it could be considered as an epidemic cluster. Beside this epidemic clone, some hospitals had their unique PFGE clone (PFGE type B'/ST2, PFGE type C'/ST2 and PFGE type D'/ST25). In those cases, it

is interesting to notice that some clones contained isolates separated by 4 years. These results suggest a successful spread of well-established clones and therefore the urgent need of effective infection control measures to eradicate such bugs.

Our *A. baumannii* strains were analyzed using four epidemiological typing techniques. PFGE was the most discriminating scheme allowing the recognition of 11 types, followed by DiversiLab with 9 types then *bla*_{OXA-51} with 8 types and finally MLST with 7 types.

To our knowledge, there is no sufficient use of adjusted Wallace coefficient in *A. baumannii* typing field, an area which has largely been expanded in the last decades. Many techniques have been proposed with an increasing trend to track this pathogen and assign it to its corresponding international clonal lineage. Therefore, there is an arising need to perform a quantitative comparison between available typing methods using this coefficient or other coefficients to assess their strengths and weaknesses, better understand and validate their fields of application.

PFGE has been considered as a gold standard for outbreak investigations due to its higher discriminatory power which impaired its use for large investigations and population structure studies. As we have shown, PFGE is a very good method to predict *bla*_{OXA-51}, MLST and rep-PCR types, but its higher resolution prevents other methods to successfully predict its types. Indeed, PFGE is a time demanding and labor intensive method with many intra and inter laboratory reproducibility problems [27]. *ApaI*, the classical restriction enzyme used for almost *A. baumannii* PFGE protocols generates complex DNA patterns with more than 40 fragments [28]. Chang *et al.*, 2013 [28] suggested the use of two other infrequent cutting restriction enzymes (*AscI* and *AsiSI*) generating clear patterns with only 10–20 fragments per pattern.

MLST is a highly informative technique which puts isolates in a global context [24] and can directly assign them to their clonal complex. Thus, it is regarded as the method of choice for long term and phylogenetic studies. Although it is a reproducible and portable method, MLST is expensive and time demanding. As expected, MLST was unable to predict PFGE and rep-PCR types because of a discriminatory power lesser than found in PFGE and rep-PCR [12, 24]. Besides, MLST could predict very well (84.7%) all *bla*_{OXA-51} sequences except the colistin resistant strain that belonged to ST2 and had an OXA-336, a single amino acid variant of OXA-66 enzyme.

DiversiLab is a commercial rep-PCR typing system which benefits from several advantages: rapidity with an ability to investigate large number of isolates, standardization, reproducibility with conserved clustering between laboratories [29], and allowing in house libraries building. For *A. baumannii*, rep-PCR had revealed a comparable discriminatory power to PFGE [15]. It has been suggested to study *A. baumannii* population structure with rep-PCR as it can identify eight international clones within 492 isolates from a worldwide collection [7] and generate concordant results with MLST and *bla*_{OXA-51} SBT [16, 30]. Our rep-PCR results showed an overall agreement with PFGE, whenever some exceptions (Fig. 1) have been noticed which explained the low adjust Wallace coefficient

(PFGE predicted 69% of rep-PCR types). Compared to PFGE clustering, rep-PCR grouped differently some strains belonging to the same PFGE type or assembled some strains belonging to different PFGE types in the same rep-PCR types, as reported with some other authors [31,32]. One discrepant result was the strain belonging to ST3 which regrouped with rep-PCR type A, whereas it had a unique PFGE type. When we visually checked the graphs of samples and overlaid functions, we noticed the presence of another peak which was the source of this confusion between strains belonging ST2/rep-PCR type A and strain ST3/rep-PCR type A. Hence, this noticed the importance of careful interpretation of rep-PCR results [31].

The *bla*_{OXA-51} gene is an intrinsic chromosomal beta-lactamase gene naturally found in *A. baumannii* and up to 95 enzyme variants have been identified to date [33]. Sequencing of the entire gene was proposed as a *bla*_{OXA-51} SBT [12]. This SBT could correctly identify the eight international clones characterized by rep-PCR [16]. Also, it correlated well with Bartual's MLST [12]. Compared with Pasteur's MLST, SBT could correctly assign the nine clonal complexes in such manner each CC had specific *bla*_{OXA-51} alleles [17]. We have found similar results, where each CC or ST had a specific *bla*_{OXA-51} variant confirmed by adjusted Wallace coefficient (*bla*_{OXA-51} SBT predict 100% all ST). Indeed, the colistin strain (strain 17) carried OXA-336 which differed only by a single amino acid from OXA-66, indicating that *bla*_{OXA-51} SBT could correctly identify it as belonging to CC2. Compared with PFGE clustering, *bla*_{OXA-51} SBT had a lower discriminatory power. *bla*_{OXA-66} characteristically linked to ST2 has been found in 3 PFGE types (A', B' and C') and one unique profile. The *bla*_{OXA-64} variant carried by ST25 had characteristically been linked to PFGE type D'. Finally, other *bla*_{OXA-51-like} variants had unique PFGE profiles.

Conclusion

This report describes the first detection of *bla*_{OXA-23} and *bla*_{OXA-24} in Lebanon. Although, our collection is unable to give the real picture of molecular epidemiology in Lebanon, it shed lights on circulating clones and on the mechanisms of carbapenem resistance. Other multi center studies are obviously required to better understand the epidemiology of this bug in the country.

Overall, a good concordance with the four typing methods was shown. PFGE and MLST are reference methods in local and long term epidemiological studies respectively, although both methods are time and cost consuming. *bla*_{OXA-51} SBT seems to be an excellent choice for initial epidemiological screening of isolates. rep-PCR is a rapid tool to access outbreaks at local scale but careful interpretation of results must be done.

Materials and Methods

Bacterial strains

A total of 42 non redundant clinical strains of *A. baumannii* isolated from various clinical samples were collected between 2006 and 2012 from the following hospitals: Rafic Harrii Beyrouth governmental hospital, Tripoli governmental hospital (TGH), Nini hospital, Rahal hospital, Monla hospital and Ain Wazein Hospital (AWH). All the bacterial strains were de-identified and a number was attributed prior to access and analysis. No consent was needed since strains used in this study were those isolated during routine analysis in the different laboratories. The clinical sources of the different strains are noted in [Table 1](#).

Identification

Isolates were routinely cultured on Blood agar at 37°C, and stored at -80°C until further study. Identification to *A. calcoaceticus-baumannii* complex was initially performed using MALDI-TOF Vitek MS (bioMérieux, Marcy-l'Étoile, France) and confirmation of identification at species level was done by real time PCR of *bla*_{OXA-51} gene [34] and partial RNA polymerase b-subunit (*rpoB*) gene sequencing [35].

Susceptibility testing and investigation of carbapenem resistance mechanisms

Antibiotic Susceptibility testing was determined by the disc diffusion method according to the guidelines of the French Society of Microbiology (www.sfm-microbiologie.org/). Resistance to carbapenem and colistin were confirmed by determining imipenem, meropenem, doripenem and colistin minimum inhibitory concentration (MICs) by Etest strips (bioMérieux, Marcy-l'Étoile, France). Carbapenem resistant isolates were investigated for the presence of carbapenem resistance genes *bla*_{OXA-23}, *bla*_{OXA-24}, *bla*_{OXA-58}, *bla*_{OXA-143}, *bla*_{ndm-1} by PCR ([Table 3](#)). Presence of the insertion sequence *ISAbal* was also screened. The association *ISAbal*-*bla*_{OXA-23} and *ISAbal*-*bla*_{OXA-51} was tested using a combination of primers *ISAbal*F with reverse primers targeting *bla*_{OXA-23} or *bla*_{OXA-51} respectively ([Table 3](#)).

Epidemiological typing

Pulsed field gel electrophoresis (PFGE)

PFGE using *Apal* as a restriction enzyme was done as described previously [36]. DNA fragments were separated in CHEF-DRIII system (Biorad, Marne LA Coquette, France) at 6V/cm and 14°C for 21 hours with pulse times ranging from 3 s to 20 s. Computer-assisted analysis was performed by using fingerprinting II (Biorad, Marne LA Coquette, France) with the unweighted pair-group method with arithmetic averages (UPGMA) and Dice similarity coefficient for banding

Table 3. Oligonucleotide primers and TaqMan* fluorescent probes used in this study.

Gene	Primer	Primer Sequences	Amplicon size (bp)	References
<i>bla</i> _{OXA51-like}	OXA51like-F	5'-AACATTAAGCACTCTTACTTATAAC	171	[22]
	OXA51like-R	5'-TTGTTGGATAACTAAAACACCCGT		
	OXA51like-Dye	FAM-CTCACCTTATATAGTGTCTGTCTAA-BHQ1		
<i>bla</i> _{OXA23-like}	OXA23-F1	5'-TGCTCTAAGCCGCGCAAATA	130	[39]
	OXA23-R1	5'-TGACCTTTTCTGCCCCTCC		
	OXA23-probe	FAM-GCCCTGATCGGATTGGAGAACCA-BHQ1		
<i>bla</i> _{OXA24-like}	OXA24-F	5'-CAAATGAGATTTTCAAATGGGATGG	123	[39]
	OXA24-R	5'-TCCGTCTTGCAAGCTCTTGAT		
	OXA24-probe	FAM-GGTGAGGCAATGGCATTGTCTAGCA-BHQ1		
<i>bla</i> _{OXA58-like}	OXA58-F	5'-CGCAGAGGGGAGAATCGTCT	102	[39]
	OXA58-R	5'-TTGCCCATCTGCCTTTTCAA		
	OXA58-probe	FAM-GGGGAATGGCTGTAGACCCGC- BHQ1		
<i>bla</i> _{OXA143-like}	OXA-143-F	5'-TGGCACTTTCAGCAGTTCT	149	[40]
	OXA-143-R	5'-TAATCTTGAGGGGGCCAACC		
<i>bla</i> _{NDM}	NDM-F	5'-GGTGCATGCCCGGTGAAATC	661	[41]
	NDM-R	5'-ATGCTGGCCTTGGGGAACG		
ISAb1	ISAb1	5'-CATTGGCATTAACTGAGGAGAAA	451	[42]
	ISAb2	5'-TTGGAAATGGGGAAAACGAA		
<i>bla</i> _{OXA51-like}	OXA-69A	5'-CTAATAATTGATCTACTCAAG	975	[12]
	OXA-69B	5'-CCAGTGGATGGATGGATAGATTATC		
<i>rpoB</i>	Ac696F	5'-TAYCGYAAAGAYTTGAAAGAAG	350	[23]
	Ac1093R	5'-CMACACCYTTGTTMCCRTGA		

*Eurofins MWG Operon, Courtaboeuf, France.

doi:10.1371/journal.pone.0115969.t003

pattern comparison. A PFGE type was defined by a cluster of isolates showing $\geq 80\%$ similarity

MLST

MLST was performed according to the Pasteur scheme (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html>). The internal fragments of seven housekeeping genes (*fusA*, *pyrG*, *rpoB*, *rplB*, *cpn60*, *gltA* and *recA*) were amplified, then purified and sequenced by an ABI 3130XL DNA sequencer (Applied Biosystems, Foster City, United States). The sequences were compared to the available sequences present in the MLST website. When a new allele or ST was identified, it was submitted and codified by Institut Pasteur MLST Database. The eBURST [37] was used to compare ST to the existed ST(s) and to assign isolates to their clonal complexes. A clonal complex (CC) is defined as a set of similar ST(s) having 6 identical loci among 7, so a CC is formed by the founder ST and its single locus variants (SLV) [10].

rep-PCR

Rep-PCR was performed using the automated system DiversiLab, version 3.4 (bioMérieux, Marcy-l'Étoile, France) following the manufacturer recommendations. Briefly, bacteria were cultured on sheep blood agar (Oxoid). DNA was extracted using the MoBio Ultra Clean microbial DNA extraction Kit, and adjusted to 50 ng/μl. After extraction, DNA was amplified using DiversiLab *Acinetobacter* kit, and the amplified DNA was separated and detected by Agilent 2100 Bioanalyser (Agilent Technologies). The resulted fingerprints were analyzed using the DiversiLab software with the modified Kullback-Leibler (KL) as a statistical method and $\geq 95\%$ as a threshold to define a cluster of closely related isolates or a rep-PCR type.

*bla*_{OXA-51} sequence-based typing (SBT)

This typing method consists to sequence the full length (825 bp) of a single locus *bla*_{OXA-51} gene. The *bla*_{OXA-51} was amplified by external primers OXA-69A/OXA-69B as described [12]. PCR products were purified and sequenced by ABI 3130xl DNA sequencer (Applied Biosystems). The resulted sequences were compared to all variants present in BLAST. When a novel variant was detected, it was submitted to GenBank and assigned by the Lahey database for beta-lactamase classification (<http://www.lahey.org/studies/webt.asp>).

Concordance between techniques

The online tool (<http://www.comparingpartitions.info/>) was used to calculate the adjusted Wallace coefficient. This coefficient is an objective and quantitative measure of clustering agreement between the studied techniques which indicates the probability of a pair of isolates assigned at the same type by one technique is also reassigned at the same by the other technique [32, 38].

Nucleotide sequence accession numbers and novel sequence types

Two new nucleotide sequences of *bla*_{OXA-51} were submitted to GenBank under accession number KF048907 and KF048908 and assigned respectively by Lahey center as *bla*_{OXA-336} and *bla*_{OXA-337}. Two new sequence types were identified and coded by MLST Pasteur as ST284 (3-5-2-1-7-1-4) and ST285 (1-52-2-2-9-4-2). The latter had a new *fusA* allele.

Ethic statement

Not applicable

Acknowledgments

We thank the team of the curators of the Institut Pasteur MLST system (Paris, France) for importing novel alleles, profiles and isolates at <http://www.pasteur.fr/>

[mlst](#). We thank also Catherine Ramont, Mariam Yehya and Taha Abdo for excellent technical assistance. A part of results of carbapenemase detection was presented at the 9th International Symposium on the Biology of *Acinetobacter*, Cologne 2013, poster presentation P5–7.

Author Contributions

Conceived and designed the experiments: MK MLJG ME FD MH. Performed the experiments: MK RR CL MPG. Analyzed the data: MK MLJG CL RR MPG. Contributed reagents/materials/analysis tools: FD MH HM RM RHS. Wrote the paper: RR MK MLJG ME.

References

1. **Kempf M, Rolain J-M** (2012) Emergence of resistance to carbapenems in *Acinetobacter baumannii* in Europe: clinical impact and therapeutic options. *Int J Antimicrob Agents* 39: 105–114. doi: 10.1016/j.ijantimicag.2011.10.004.
2. **Karah N, Sundsfjord A, Towner K, Samuelsen Ø** (2012) Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. *Drug Resist Updat* 15: 237–247. doi: 10.1016/j.drug.2012.06.001.
3. **Zarrilli R, Pournaras S, Giannouli M, Tsakris A** (2013) Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages. *Int J Antimicrob Agents* 41: 11–19. doi: 10.1016/j.ijantimicag.2012.09.008.
4. **Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann M, et al.** (1996) Comparison of outbreak and nonoutbreak *Acinetobacter baumannii* strains by genotypic and phenotypic methods. *J Clin Microbiol* 34: 1519–1525.
5. **Van Dessel H, Dijkshoorn L, Van Der Reijden T, Bakker N, Paauw A, et al.** (2004) Identification of a new geographically widespread multiresistant *Acinetobacter baumannii* clone from European hospitals. *Res Microbiol* 155: 105–112.
6. **Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, et al.** (2005) Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of *Acinetobacter baumannii*. *J Clin Microbiol* 43: 4328–4335. doi: 10.1128/JCM.43.9.4328-4335.2005.
7. **Higgins PG, Dammhayn C, Hackel M, Seifert H** (2010) Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 65: 233–238. doi: 10.1093/jac/dkp428.
8. **Nemec A, Dijkshoorn L, van der Reijden TJK** (2004) Long-term predominance of two pan-European clones among multi-resistant *Acinetobacter baumannii* strains in the Czech Republic. *J Med Microbiol* 53: 147.
9. **Bartual SG, Seifert H, Hippler C, Luzon MAD, Wisplinghoff H, et al.** (2005) Development of a multilocus sequence typing scheme for characterization of clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol* 43: 4382–4390. doi: 10.1128/JCM.43.9.4382-4390.2005.
10. **Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S** (2010) The Population Structure of *Acinetobacter baumannii*: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool. *PLoS ONE* 5: e10034. doi: 10.1371/journal.pone.0010034.
11. **Turton J, Gabriel S, Valderrey C, Kaufmann M, Pitt T** (2007) Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of *Acinetobacter baumannii*. *Clin Microbiol Infect* 13: 807–815.
12. **Hamouda A, Evans BA, Towner KJ, Amyes SGB** (2010) Characterization of epidemiologically unrelated *Acinetobacter baumannii* isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes. *J Clin Microbiol* 48: 2476–2483.

13. **Pourcel C, Minandri F, Hauck Y, D'Arezzo S, Imperi F, et al.** (2011) Identification of variable-number tandem-repeat (VNTR) sequences in *Acinetobacter baumannii* and interlaboratory validation of an optimized multiple-locus VNTR analysis typing scheme. *J Clin Microbiol* 49: 539–548. doi: 10.1128/JCM.02003-10.
14. **Grosso F, Carvalho KR, Quinteira S, Ramos A, Carvalho-Assef APD, et al.** (2011) OXA-23-Producing *Acinetobacter Baumannii*: A New Hotspot of Diversity in Rio De Janeiro? *J Antimicrob Chemother* 66: 62–65. doi: 10.1093/jac/dkq406.
15. **Grisold A, Zarfel G, Strenger V, Feierl G, Leitner E, et al.** (2010) Use of automated repetitive-sequence-based PCR for rapid laboratory confirmation of nosocomial outbreaks. *J Infect* 60: 44–51.
16. **Zander E, Nemec A, Seifert H, Higgins PG** (2012) Association between β -lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of *Acinetobacter baumannii* isolates. *J Clin Microbiol* 50: 1900–1904. doi: 10.1128/JCM.06462-11.
17. **Pournaras S, Gogou V, Giannouli M, Dimitroulia E, Dafopoulou K, et al.** (2014) Single locus sequence-based typing of blaOXA-51-like gene for rapid classification of *Acinetobacter baumannii* clinical isolates to international clones. *J Clin Microbiol*. doi: 10.1128/JCM.03565-13.
18. **Zarrilli R, Vitale D, Di Popolo A, Bagattini M, Daoud Z, et al.** (2008) A plasmid-borne blaOXA-58 gene confers imipenem resistance to *Acinetobacter baumannii* isolates from a Lebanese hospital. *Antimicrob Agents Chemother* 52: 4115–4120. doi: 10.1128/AAC.00366-08.
19. **Giannouli M, Tomasone F, Agodi A, Vahaboglu H, Daoud Z, et al.** (2009) Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* strains in intensive care units of multiple Mediterranean hospitals. *J Antimicrob Chemother* 63: 828–830. doi: 10.1093/jac/dkp032.
20. **Di Popolo A, Giannouli M, Triassi M, Brisse S, Zarrilli R** (2011) Molecular epidemiological investigation of multidrug-resistant *Acinetobacter baumannii* strains in four Mediterranean countries with a multilocus sequence typing scheme. *Clin Microbiol Infect Dis* 17: 197–201. doi: 10.1111/j.1469-0691.2010.03254.x.
21. **Rafei R, Dabboussi F, Hamze M, Eveillard M, Lemarié C, et al.** (2014) First report of blaNDM-1-producing *Acinetobacter baumannii* isolated in Lebanon from civilians wounded during the Syrian war. *Int J Infect Dis* 21: 21–23. doi: 10.1016/j.ijid.2014.01.004.
22. **Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian G-B, Marschall J, et al.** (2011) Molecular epidemiology of carbapenem-nonsusceptible *Acinetobacter baumannii* in the United States. *J Clin Microbiol* 49: 3849–3854. doi: 10.1128/JCM.00619-11.
23. **Schleicher X, Higgins PG, Wisplinghoff H, Körber-Irrgang B, Kresken M, et al.** (2013) Molecular epidemiology of *Acinetobacter baumannii* and *Acinetobacter nosocomialis* in Germany over a 5-year period (2005–2009). *Clin Microbiol Infect* 19: 737–742. doi: 10.1111/1469-0691.12026.
24. **Runnegar N, Sidjabat H, Goh HMS, Nimmo GR, Schembri MA, et al.** (2010) Molecular epidemiology of multidrug-resistant *Acinetobacter baumannii* in a single institution over a 10-year period. *J Clin Microbiol* 48: 4051–4056. doi: 10.1128/JCM.01208-10.
25. **Minandri F, D'Arezzo S, Antunes LCS, Pourcel C, Principe L, et al.** (2012) Evidence of diversity among epidemiologically related carbapenemase-producing *Acinetobacter baumannii* strains belonging to international clonal lineage II. *J Clin Microbiol* 50: 590–597. doi: 10.1128/JCM.05555-11.
26. **Grosso F, Quinteira S, Peixe L** (2011) Understanding the dynamics of imipenem-resistant *Acinetobacter baumannii* lineages within Portugal. *Clin Microbiol Infect Dis* 17: 1275–1279. doi: 10.1111/j.1469-0691.2011.03469.x.
27. **Li W, Raoult D, Fournier P-E** (2009) Bacterial strain typing in the genomic era. *FEMS Microbiol Rev* 33: 892–916. doi: 10.1111/j.1574-6976.2009.00182.x.
28. **Chang K-M, Huang W-C, Chiou C-S, Shen G-H, Huang C-C, et al.** (2013) Suitable restriction enzyme for standardization of pulsed-field gel electrophoresis protocol and interlaboratory comparison of *Acinetobacter baumannii*. *J Microbiol Immunol Infect* 46: 195–201. doi: 10.1016/j.jmii.2012.05.011.
29. **Higgins PG, Hujer AM, Hujer KM, Bonomo RA, Seifert H** (2012) Interlaboratory reproducibility of DiversiLab rep-PCR typing and clustering of *Acinetobacter baumannii* isolates. *J Med Microbiol* 61: 137–141. doi: 10.1099/jmm.0.036046-0.
30. **Higgins PG, Janßen K, Fresen MM, Wisplinghoff H, Seifert H** (2012) Molecular Epidemiology of *Acinetobacter baumannii* Bloodstream Isolates Obtained in the United States from 1995 to 2004 Using rep-PCR and Multilocus Sequence Typing. *J Clin Microbiol* 50: 3493–3500. doi: 10.1128/JCM.01759-12.

31. **Schuetz AN, Huard RC, Eshoo MW, Massire C, Della-Latta P, et al.** (2012) Identification of a novel *Acinetobacter baumannii* clone in a US hospital outbreak by multilocus polymerase chain reaction/ electrospray-ionization mass spectrometry. *Diagn Microbiol Infect Dis* 72: 14–19. doi: 10.1016/j.diagmicrobio.2011.09.012.
32. **Maâtallah M, Bakhrouf A, Habeeb MA, Turlej-Rogacka A, Iversen A, et al.** (2013) Four Genotyping Schemes for Phylogenetic Analysis of *Pseudomonas aeruginosa*: Comparison of Their Congruence with Multi-Locus Sequence Typing. *PLoS ONE* 8: e82069. doi: 10.1371/journal.pone.0082069.
33. **Evans BA, Amyes SGB** (2014) OXA β -Lactamases. *Clin Microbiol Rev* 27: 241–263. doi: 10.1128/CMR.00117-13.
34. **Kempf M, Rolain J-M, Diatta G, Azza S, Samb B, et al.** (2012) Carbapenem resistance and *Acinetobacter baumannii* in Senegal: the paradigm of a common phenomenon in natural reservoirs. *PLoS One* 7: e39495. doi: 10.1371/journal.pone.0039495.
35. **Gundi VAKB, Dijkshoorn L, Burignat S, Raoult D, La Scola B** (2009) Validation of partial *rpoB* gene sequence analysis for the identification of clinically important and emerging *Acinetobacter* species. *Microbiology* 155: 2333–2341. doi: 10.1099/mic.0.026054-0.
36. **Kempf M, Rolain J-M, Azza S, Diene S, Joly-Guillou M-L, et al.** (2012) Investigation of *Acinetobacter baumannii* resistance to carbapenems in Marseille hospitals, south of France: a transition from an epidemic to an endemic situation. *Acta Pathol Microbiol Immunol Scand*. doi: 10.1111/j.1600-0463.2012.02935.x.
37. **Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG** (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. *J Bacteriol* 186: 1518–1530.
38. **Severiano A, Pinto FR, Ramirez M, Carrico JA** (2011) Adjusted Wallace Coefficient as a Measure of Congruence between Typing Methods. *J Clin Microbiol* 49: 3997–4000. doi: 10.1128/JCM.00624-11.
39. **Mesli E, Berrazeg M, Drissi M, Bekkhoucha SN, Rolain J-M** (2013) Prevalence of carbapenemase-encoding genes including New Delhi metallo- β -lactamase in *Acinetobacter* species, Algeria. *Int J Infect Dis* 17: e739–e743. doi: 10.1016/j.ijid.2013.02.024.
40. **Higgins PG, Lehmann M, Seifert H** (2010) Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents* 35: 305. doi: 10.1016/j.ijantimicag.2009.10.014.
41. **Bonnin RA, Naas T, Poirel L, Nordmann P** (2012) Phenotypic, Biochemical, and Molecular Techniques for Detection of Metallo- β -Lactamase NDM in *Acinetobacter baumannii*. *J Clin Microbiol* 50: 1419–1421. doi: 10.1128/JCM.06276-11.
42. **Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J** (2007) Prevalence of IS(Aba1) in epidemiologically unrelated *Acinetobacter baumannii* clinical isolates. *Clin Microbiol Infect Dis* 13: 1192–1198.